The risk of stent clot (thrombosis) is significantly increased in patients who demonstrate resistance to the drug clopidogrel.
GRAVITAS trial compared a high to a standard dose of clopidogrel in over 2000 such patients and showed no difference in the incidence of major cardiovascular events at six months.
Source: JAMA 2011; 305:1097
No comments:
Post a Comment